IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms

The recurrent V617F mutation in JAK2 (JAK2(V617F)) has emerged as the primary contributor to the pathogenesis of myeloproliferative neoplasms (MPN). However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indicates the need for identifying pathways tha...

Descripción completa

Detalles Bibliográficos
Autores principales: de Melo Campos, Paula, Machado-Neto, João A., Eide, Christopher A., Savage, Samantha L., Scopim-Ribeiro, Renata, da Silva Souza Duarte, Adriana, Favaro, Patricia, Lorand-Metze, Irene, Costa, Fernando F., Tognon, Cristina E., Druker, Brian J., Saad, Sara T. Olalla, Traina, Fabiola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872760/
https://www.ncbi.nlm.nih.gov/pubmed/26755644
http://dx.doi.org/10.18632/oncotarget.6851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872760/
https://www.ncbi.nlm.nih.gov/pubmed/26755644
http://dx.doi.org/10.18632/oncotarget.6851

Ejemplares similares